Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.
He Y, Davies CM, Harrington BS, Hellmers L, Sheng Y, Broomfield A, McGann T, Bastick K, Zhong L, Wu A, Maresh G, McChesney S, Yau Wong K, Adams MN, Sullivan RC, Palmer JS, Burke LJ, Ewing AD, Zhang X, Margolin D, Li L, Lourie R, Matsika A, Srinivasan B, McGuckin MA, Lumley JW, Hooper JD. He Y, et al. Among authors: davies cm. Oncogene. 2020 Jan;39(1):219-233. doi: 10.1038/s41388-019-0983-3. Epub 2019 Aug 30. Oncogene. 2020. PMID: 31471585
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
Adams MN, Harrington BS, He Y, Davies CM, Wallace SJ, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. Adams MN, et al. Among authors: davies cm. Oncogene. 2015 Mar 12;34(11):1375-83. doi: 10.1038/onc.2014.88. Epub 2014 Mar 31. Oncogene. 2015. PMID: 24681947
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. He Y, et al. Among authors: davies cm. Oncogene. 2016 Jan 28;35(4):468-78. doi: 10.1038/onc.2015.101. Epub 2015 Apr 20. Oncogene. 2016. PMID: 25893298
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, Roche DK, Kennedy C, Chetty NP, Crandon AJ, Flatley C, Oliveira NB, Shannon CM, deFazio A, Tinker AV, Gilks CB, Gabrielli B, Brennan DJ, Coward JI, Armes JE, Perrin LC, Hooper JD. Harrington BS, et al. Among authors: davies cm. Br J Cancer. 2016 Feb 16;114(4):417-26. doi: 10.1038/bjc.2015.471. Epub 2016 Feb 4. Br J Cancer. 2016. PMID: 26882065 Free PMC article.
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer.
He Y, Khan T, Kryza T, Jones ML, Goh JB, Lyons NJ, Pearce LA, Lee MD, Gough M, Rogers R, Davies CM, Gilks CB, Hodgkinson T, Lourie R, Barry SC, Perrin LC, Williams CC, Puttick S, Adams TE, Munro TP, Hooper JD, Chetty N. He Y, et al. Among authors: davies cm. Mol Pharm. 2021 Sep 6;18(9):3464-3474. doi: 10.1021/acs.molpharmaceut.1c00401. Epub 2021 Aug 27. Mol Pharm. 2021. PMID: 34448393
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Khan T, et al. Among authors: davies cm. Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869. Cancers (Basel). 2020. PMID: 32260077 Free PMC article.
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.
Nguyen THM, Carreira PE, Sanchez-Luque FJ, Schauer SN, Fagg AC, Richardson SR, Davies CM, Jesuadian JS, Kempen MHC, Troskie RL, James C, Beaven EA, Wallis TP, Coward JIG, Chetty NP, Crandon AJ, Venter DJ, Armes JE, Perrin LC, Hooper JD, Ewing AD, Upton KR, Faulkner GJ. Nguyen THM, et al. Among authors: davies cm. Cell Rep. 2018 Jun 26;23(13):3730-3740. doi: 10.1016/j.celrep.2018.05.090. Cell Rep. 2018. PMID: 29949758 Free article.
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF, Kondrashova O, Smith D, Nones K, Sengal AT, Ju R, Packer LM, Koufariotis LT, Kazakoff SH, Davidson AL, Ramarao-Milne P, Lakis V, Newell F, Rogers R, Davies C, Nicklin J, Garrett A, Chetty N, Perrin L, Pearson JV, Patch AM, Waddell N, Pollock PM. Bonazzi VF, et al. Genome Med. 2022 Jan 10;14(1):3. doi: 10.1186/s13073-021-00990-z. Genome Med. 2022. PMID: 35012638 Free PMC article.
ER and PR expression and survival after endometrial cancer.
Smith D, Stewart CJR, Clarke EM, Lose F, Davies C, Armes J, Obermair A, Brennan D, Webb PM, Nagle CM, Spurdle AB. Smith D, et al. Among authors: davies c. Gynecol Oncol. 2018 Feb;148(2):258-266. doi: 10.1016/j.ygyno.2017.11.027. Epub 2017 Dec 6. Gynecol Oncol. 2018. PMID: 29217139
73 results